vs
伊士曼化工（EMN）与Solventum（SOLV）财务数据对比。点击上方公司名可切换其他公司
Solventum的季度营收约是伊士曼化工的1.0倍（$2.0B vs $2.0B），伊士曼化工净利率更高（5.3% vs 3.2%，领先2.2%），Solventum同比增速更快（-3.7% vs -13.8%），过去两年Solventum的营收复合增速更高（-0.4% vs -8.6%）
伊士曼化工是总部位于美国田纳西州金斯波特的全球特种材料企业，前身为柯达子公司，1920年成立，1994年独立运营。公司在全球拥有36个生产基地、约1.4万名员工，生产各类先进材料、化学品和纤维产品，广泛应用于日常生活领域，2023年销售额约92.1亿美元。
Solventum是一家总部位于美国的医疗健康企业，于2024年4月1日正式从全球知名多元化工业集团3M分拆后独立运营，继承了原3M旗下医疗板块的技术积累与业务资源，面向全球市场提供专业医疗相关产品及服务。
EMN vs SOLV — 直观对比
营收规模更大
SOLV
是对方的1.0倍
$2.0B
营收增速更快
SOLV
高出10.1%
-13.8%
净利率更高
EMN
高出2.2%
3.2%
两年增速更快
SOLV
近两年复合增速
-8.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $2.0B |
| 净利润 | $105.0M | $63.0M |
| 毛利率 | 17.1% | 51.4% |
| 营业利润率 | — | 6.3% |
| 净利率 | 5.3% | 3.2% |
| 营收同比 | -13.8% | -3.7% |
| 净利润同比 | -42.3% | 103.2% |
| 每股收益（稀释后） | $0.93 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMNSOLV
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $2.0B | ||
| Q3 25 | $2.2B | $2.1B | ||
| Q2 25 | $2.3B | $2.2B | ||
| Q1 25 | $2.3B | $2.1B | ||
| Q4 24 | $2.2B | $2.1B | ||
| Q3 24 | $2.5B | $2.1B | ||
| Q2 24 | $2.4B | $2.1B |
净利润EMNSOLV
| Q1 26 | $105.0M | — | ||
| Q4 25 | $105.0M | $63.0M | ||
| Q3 25 | $47.0M | $1.3B | ||
| Q2 25 | $140.0M | $90.0M | ||
| Q1 25 | $182.0M | $137.0M | ||
| Q4 24 | $330.0M | $31.0M | ||
| Q3 24 | $180.0M | $122.0M | ||
| Q2 24 | $230.0M | $89.0M |
毛利率EMNSOLV
| Q1 26 | 17.1% | — | ||
| Q4 25 | 17.1% | 51.4% | ||
| Q3 25 | 19.7% | 54.2% | ||
| Q2 25 | 22.1% | 54.4% | ||
| Q1 25 | 24.8% | 53.8% | ||
| Q4 24 | 24.7% | 53.9% | ||
| Q3 24 | 24.6% | 56.0% | ||
| Q2 24 | 25.3% | 54.6% |
营业利润率EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | 0.6% | 6.3% | ||
| Q3 25 | 6.1% | 80.6% | ||
| Q2 25 | 7.4% | 9.9% | ||
| Q1 25 | 11.0% | 7.3% | ||
| Q4 24 | 13.2% | 6.6% | ||
| Q3 24 | 11.4% | 13.2% | ||
| Q2 24 | 12.1% | 11.7% |
净利率EMNSOLV
| Q1 26 | 5.3% | — | ||
| Q4 25 | 5.3% | 3.2% | ||
| Q3 25 | 2.1% | 60.4% | ||
| Q2 25 | 6.1% | 4.2% | ||
| Q1 25 | 7.9% | 6.6% | ||
| Q4 24 | 14.7% | 1.5% | ||
| Q3 24 | 7.3% | 5.9% | ||
| Q2 24 | 9.7% | 4.3% |
每股收益（稀释后）EMNSOLV
| Q1 26 | $0.93 | — | ||
| Q4 25 | $0.93 | $0.37 | ||
| Q3 25 | $0.40 | $7.22 | ||
| Q2 25 | $1.20 | $0.51 | ||
| Q1 25 | $1.57 | $0.78 | ||
| Q4 24 | $2.81 | $0.18 | ||
| Q3 24 | $1.53 | $0.70 | ||
| Q2 24 | $1.94 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $566.0M | $878.0M |
| 总债务越低越好 | — | $5.0B |
| 股东权益账面价值 | $6.0B | $5.0B |
| 总资产 | $14.9B | $14.3B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资EMNSOLV
| Q1 26 | $566.0M | — | ||
| Q4 25 | $566.0M | $878.0M | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $492.0M | ||
| Q1 25 | — | $534.0M | ||
| Q4 24 | $837.0M | $762.0M | ||
| Q3 24 | — | $772.0M | ||
| Q2 24 | — | $897.0M |
总债务EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | $5.1B | ||
| Q2 25 | — | $7.8B | ||
| Q1 25 | — | $7.9B | ||
| Q4 24 | — | $8.0B | ||
| Q3 24 | — | $8.1B | ||
| Q2 24 | — | $8.3B |
股东权益EMNSOLV
| Q1 26 | $6.0B | — | ||
| Q4 25 | $6.0B | $5.0B | ||
| Q3 25 | $5.8B | $5.0B | ||
| Q2 25 | $5.8B | $3.6B | ||
| Q1 25 | $5.9B | $3.3B | ||
| Q4 24 | $5.8B | $3.0B | ||
| Q3 24 | $5.7B | $3.2B | ||
| Q2 24 | $5.6B | $2.9B |
总资产EMNSOLV
| Q1 26 | $14.9B | — | ||
| Q4 25 | $14.9B | $14.3B | ||
| Q3 25 | $15.0B | $14.0B | ||
| Q2 25 | $15.2B | $15.1B | ||
| Q1 25 | $15.0B | $14.5B | ||
| Q4 24 | $15.2B | $14.5B | ||
| Q3 24 | $15.1B | $14.7B | ||
| Q2 24 | $14.9B | $14.6B |
负债/权益比EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 2.14× | ||
| Q1 25 | — | 2.43× | ||
| Q4 24 | — | 2.71× | ||
| Q3 24 | — | 2.54× | ||
| Q2 24 | — | 2.90× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $95.0M |
| 自由现金流经营现金流 - 资本支出 | — | $32.0M |
| 自由现金流率自由现金流/营收 | — | 1.6% |
| 资本支出强度资本支出/营收 | — | 3.2% |
| 现金转化率经营现金流/净利润 | — | 1.51× |
| 过去12个月自由现金流最近4个季度 | — | $-10.0M |
8季度趋势，按日历期对齐
经营现金流EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | $502.0M | $95.0M | ||
| Q3 25 | $402.0M | $76.0M | ||
| Q2 25 | $233.0M | $169.0M | ||
| Q1 25 | $-167.0M | $29.0M | ||
| Q4 24 | $540.0M | $219.0M | ||
| Q3 24 | $396.0M | $169.0M | ||
| Q2 24 | $367.0M | $355.0M |
自由现金流EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | $390.0M | $32.0M | ||
| Q3 25 | $265.0M | $-21.0M | ||
| Q2 25 | $83.0M | $59.0M | ||
| Q1 25 | $-314.0M | $-80.0M | ||
| Q4 24 | $361.0M | $92.0M | ||
| Q3 24 | $276.0M | $76.0M | ||
| Q2 24 | $252.0M | $297.0M |
自由现金流率EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | 19.8% | 1.6% | ||
| Q3 25 | 12.0% | -1.0% | ||
| Q2 25 | 3.6% | 2.7% | ||
| Q1 25 | -13.7% | -3.9% | ||
| Q4 24 | 16.1% | 4.4% | ||
| Q3 24 | 11.2% | 3.7% | ||
| Q2 24 | 10.7% | 14.3% |
资本支出强度EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 3.2% | ||
| Q3 25 | 6.2% | 4.6% | ||
| Q2 25 | 6.6% | 5.1% | ||
| Q1 25 | 6.4% | 5.3% | ||
| Q4 24 | 8.0% | 6.1% | ||
| Q3 24 | 4.9% | 4.5% | ||
| Q2 24 | 4.9% | 2.8% |
现金转化率EMNSOLV
| Q1 26 | — | — | ||
| Q4 25 | 4.78× | 1.51× | ||
| Q3 25 | 8.55× | 0.06× | ||
| Q2 25 | 1.66× | 1.88× | ||
| Q1 25 | -0.92× | 0.21× | ||
| Q4 24 | 1.64× | 7.06× | ||
| Q3 24 | 2.20× | 1.39× | ||
| Q2 24 | 1.60× | 3.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMN
暂无分部数据
SOLV
| Infection Prevention And Surgical Solutions | $752.0M | 38% |
| Cost Of Software And Rentals | $508.0M | 25% |
| Health Information Systems Segment | $347.0M | 17% |
| Dental Solutions Segment | $343.0M | 17% |
| Related Party | $14.0M | 1% |
